Prem Soman

Prem Soman

Cardiology

200 Lothrop Street, UPMC Presbyterian 5B Cardiology
Pittsburgh, PA 15213

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 148 publications

Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial.

Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial.

Journal: Journal of the American Heart Association

Published: August 31, 2026

Effect of acoramidis on risk of death and heart problem-related hospitalizations in people with transthyretin amyloid cardiomyopathy: a plain language summary.

Effect of acoramidis on risk of death and heart problem-related hospitalizations in people with transthyretin amyloid cardiomyopathy: a plain language summary.

Journal: Future cardiology

Published: August 05, 2026

Corrigendum to "The evolution of Tc-99m-labeled cardiac amyloid radionuclide imaging for transthyretin cardiomyopathy: Current state-of-the-art" [J Nucl Cardiol 59(S) (2026) 102735].

Corrigendum to "The evolution of Tc-99m-labeled cardiac amyloid radionuclide imaging for transthyretin cardiomyopathy: Current state-of-the-art" [J Nucl Cardiol 59(S) (2026) 102735].

Journal: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Published: June 29, 2026

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM.

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM.

Journal: Journal of cardiac failure

Published: May 08, 2026

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM.

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM.

Journal: Journal of cardiac failure

Published: May 08, 2026

The evolution of Tc-99m- labeled cardiac amyloid radionuclide imaging for transthyretin cardiomyopathy: Current state-of-the-art.

The evolution of Tc-99m- labeled cardiac amyloid radionuclide imaging for transthyretin cardiomyopathy: Current state-of-the-art.

Journal: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Published: April 13, 2026

Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial.

Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial.

Journal: JAMA cardiology

Published: March 30, 2026

Clinical indications for positron emission tomography myocardial perfusion imaging and myocardial blood flow quantification: An American Society of Nuclear Cardiology position statement.

Clinical indications for positron emission tomography myocardial perfusion imaging and myocardial blood flow quantification: An American Society of Nuclear Cardiology position statement.

Journal: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Published: January 02, 2026

A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.

A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.

Journal: Future cardiology

Published: December 12, 2025

Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study.

Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study.

Journal: Journal of the American Heart Association

Published: November 26, 2025

Differential Transthyretin Stabilization in Patients With Wild Type and Variant Transthyretin Amyloidosis.

Differential Transthyretin Stabilization in Patients With Wild Type and Variant Transthyretin Amyloidosis.

Journal: JACC. CardioOncology

Published: November 11, 2025

Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension.

Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension.

Journal: JAMA cardiology

Published: November 08, 2025

Showing 1-12 of 148

Last Updated: 09/26/2026